Comparative Pharmacology
Head-to-head clinical analysis: BOSULIF versus BOSUTINIB MONOHYDRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSULIF versus BOSUTINIB MONOHYDRATE.
BOSULIF vs BOSUTINIB MONOHYDRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bosutinib is a tyrosine kinase inhibitor that targets BCR-ABL kinase, as well as SRC family kinases. It inhibits the phosphorylation of tyrosine residues in proteins involved in the BCR-ABL signaling pathway, thereby inhibiting cell proliferation and inducing apoptosis in Philadelphia chromosome-positive (Ph+) leukemia cells.
Bosutinib is a dual Src/Abl tyrosine kinase inhibitor. It inhibits the BCR-ABL kinase, which is constitutively active in chronic myeloid leukemia (CML), and also inhibits Src family kinases. It has minimal inhibitory activity against c-KIT and PDGFR.
400 mg orally once daily with food.
400 mg orally once daily with food.
None Documented
None Documented
The terminal elimination half-life is approximately 22.5 hours (range 15-34 hours) following a 500 mg oral dose. This supports once-daily dosing, with steady-state achieved within 15 days.
22.5 hours; supports once-daily dosing, with steady-state achieved by day 8.
Primarily fecal (approximately 85% of the administered dose), with renal excretion accounting for less than 1% as unchanged drug and 3% as metabolites. Biliary excretion is a significant route for elimination of unchanged drug and metabolites.
Primarily fecal (91%, as unchanged drug and metabolites) with renal excretion accounting for <3%.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor